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Available online 2 March 2016Natural Killer (NK) cells have been shown to exert antiviral and antitumoural activities. Neverthelessmost avail-
able data are derived from mouse models and functions of these cells in human remain unclear. To evaluate the
impact of low circulating NK cell counts and to provide some clues to the role of NK cells in natural conditions,we
studied a large cohort of patients with common variable immunodeﬁciency (CVID) included in a multicenter co-
hort of patients with primary hypogammaglobulinaemia. Patients were classiﬁed into three groups on the basis
of their NK cell counts: severe and mild NK cell lymphopenia (b50 and 50–99 × 106/L respectively), and normal
NK cell counts (N100 × 106/L). Clinical events were analyzed and compared between these three groups of pa-
tients. During study period, 457 CVID patients were included: 99 (21.7%) with severe NK cell lymphopenia,
118 (25.8%) withmild NK cell lymphopenia and 240 (52.5%) with normal NK cell counts. Non-infectious compli-
cations (57% vs. 36% and 35%), and, particularly, granulomatous complications (25.3% vs. 13.6% and 8.8%), were
more frequent in patients with severe NK cell lymphopenia than in other groups. Invasive infections (68.7% vs.
60.2% and 48.8%), including bacteraemia (22.2% vs. 5.9% and 8.3%) and infectious pneumonia (63.6% vs. 59.3%
and 44.2%), were also more frequent in this population. However, no difference was observed for viral infections
and neoplasms. Low circulating NK cell counts are associated with more severe phenotypes of CVID, which may
indicate a protective role of these immune cells against severe bacterial infections and other complications and
non-redundant immune functions when the adaptive immune response is not optimal.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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223M. Ebbo et al. / EBioMedicine 6 (2016) 222–2301. IntroductionNatural Killer (NK) cells are cytolytic innate lymphoid cells (ILCs)
that secrete an array of cytokines and chemokines (Spits et al., 2013;
Vivier et al., 2011). Our knowledge of the biology of these cells has
greatly increased over the last two decades, but the exact functions of
human NK cells in vivo remain elusive. Indeed, the principal known
functions of NK cells, such as the control of viral infections and cancers,
were identiﬁed in studies on mice, and few data are available for
humans (Vivier et al., 2011). Onemajor obstacle to be overcome in stud-
ies of the role of NK cells in humans is the rarity of selective andwell de-
ﬁned NK cell deﬁciencies (Jouanguy et al., 2013). Isolated NK cell
deﬁciencies are exceptional, and full clinical phenotypes are not always
available for the rare affected patients (Gineau et al., 2012;Hughes et al.,
2012; Casey et al., 2012). It has been suggested that isolatedNK cell lym-
phopenia is not associated with a particular clinical phenotype. This is
the case in children with severe combined immunodeﬁciencies (SCID)
with an NK− phenotype before hematopoietic stem cell transplanta-
tion (HSCT). The NK cell compartment is not successfully reconstituted
after HSCT in a signiﬁcant proportion of these patients (low NK cell
count b 50×106/L), and the incidence of clinical events in these patients
is similar to that in patients with normal NK cell counts (Neven et al.,
2009). This may reﬂect redundancy between NK cell responses and
other types of immune response, as such redundancy is frequently ob-
served in immunity (Nish and Medzhitov, 2011). We therefore rea-
soned that the impact of an NK cell deﬁciency might be revealed by
studies of patients presenting other immune defects. We explored the
clinical phenotypes of patients with severe NK cell lymphopenia and
compared them with those of patients with mild or normal NK cell
counts, in a large cohort of patients with common variable immunode-
ﬁciency (CVID) from the French DEFI study.
2. Materials and Methods
DEFI is a French national study set up in 2004 to collect clinical
data and biological specimens from adult patients with primary
hypogammaglobulinaemia (Oksenhendler et al., 2008). The inclu-
sion criteria in the DEFI study were adult patients with primary
hypogammaglobulinaemia (serum IgG concentration b 5 g/L, or a serum
IgA concentration b 0.7 g/L, or a serum IgM concentration b 0.4 g/L, or
IgG subclass deﬁciency). The exclusion criteria were secondary
hypogammaglobulinaemia and refusal to participate.
In total, 691 patients were included in the DEFI study. We present
here the characteristics of 457 patients from 47 centers enrolled in the
study between April 2004 and April 2013, all of whom were diagnosed
with CVID. The diagnostic criteria used for CVID diagnosis were consis-
tent with the European Society for Immune Deﬁciencies/Pan-American
Group for Immunodeﬁciency criteria (Conley et al., 1999): (Spits et al.,
2013) markedly low IgG levels (at least 2 SD below the mean for age)
andmarkedly low levels of IgM, IgA, or both, (Vivier et al., 2011) a diag-
nosis of immunodeﬁciency after the age of two years, and (Jouanguy
et al., 2013) no other known cause of hypogammaglobulinaemia.
Screening of the genes encoding the CD40 ligand, the signalling lym-
phocyte activation molecule-associated protein, and Bruton's tyrosine
kinase, was performed inmale patients in the DEFI study, to exclude pa-
tients with X-linked hyper-IgM, X-linked lymphoproliferative disease,
and X-linked agammaglobulinaemia, respectively, and AICDA (Activa-
tion-induced cytidine deaminase) was also sequenced to exclude pa-
tients with an autosomal recessive form of hyper-IgM from the CVID
group.
The patients were enrolled in the study prospectively, and blood
samples were collected, analyzed, and stored at inclusion. Clinical data
were then collected retrospectively. The clinical ﬁle of each patient in-
cluded a retrospective analysis of the patient's infectious, autoimmune,
lymphoproliferative, and tumoural complications, and the patient's
family medical history. A blood sample collected at inclusion was usedfor the determination of detailed T, B and NK cell phenotypes at the
same centralized reference laboratory for all patients. All patients gave
written informed consent for participation, including possible inclusion
in genetic studies, and the study was approved by the local ethics com-
mittee. The clinical and biological database is centralized at the Depart-
ment of Clinical Immunology of Saint-Louis Hospital in Paris. Clinicians
were asked to inform the principal investigator of any signiﬁcant clinical
events during follow-up.
Patients were assigned to three groups on the basis of their NK cell
counts (NK cells were deﬁned as CD3−CD56+CD16+ cells) at inclusion.
Less than 5% of healthy controls have NK cell counts below 50 x106/L
(Supplemental data Fig. S1, obtained in 145 healthy adults in our spe-
cialized NK cell laboratory). In another independent cohort of 52
blood healthy donors, median NK cell count was 185 × 106/L (IQR,
115–270), with no case below 50 × 106/L (data not shown). This last
populationwas the reference population used in the reference laborato-
ry of theDEFI study.We therefore used a cut-off of 50NK cells × 106/L to
deﬁne severe NK cell lymphopenia. Patients were also considered to
have mild NK cell deﬁciency if they had NK cell counts between 50
and 99 cells × 106/L, and normal counts if their NK cell counts were
≥100 cells × 106/L at the time of evaluation. Clinical events and biolog-
ical characteristics of patients with severe NK cell deﬁciency, mild NK
cell deﬁciency and normal NK cell counts were analyzed and compared
between groups.
Opportunistic infections (OIs)were consistent with the revised clas-
siﬁcation system of the manifestations of human immunodeﬁciency
virus (HIV) infection and deﬁnition for AIDS from CDC (From the
Centers for Disease Control and Prevention, 1993) and were referred
to asOIs. Some atypical infections, such as pulmonary tuberculosis or re-
current herpes infections, are not included in these opportunistic infec-
tions and should be distinguished from “usual infections” during CVID
(essentially ENT and respiratory bacterial infections by usual infectious
agents). Instead, they were referred to as “unusual infections” (Supple-
mental data Table S1). Other clinical events were deﬁned as previously
described (Chapel et al., 2008, 2012). Lymphoid hyperplasia was de-
ﬁned as any follicular hyperplasia or polymorph lymphoid inﬁltrate
(without argument for lymphoma) occurring within lymphoid organ
(lymphadenopathy, spleen, tonsils, cavum) or within extra-nodal/
extra-lymphoid organ. Autoimmune disease was deﬁned as any auto-
immune disease excluding autoimmune cytopenia (rheumatoid arthri-
tis, systemic lupus erythematosus, Sjögren syndrome, autoimmune
thyroiditis, Biermer disease, type 1 diabetes, inﬂammatory myositis…).
Finally enteropathy was deﬁned as any cause of recurrent acute diar-
rhea or chronic diarrhea, including celiac-like villous atrophy and
Crohn's-like inﬂammatory bowel disease. Documented granuloma,
lymphoid hyperplasia or lymphoma in the gut were not included in
this category but in the corresponding ones (respectively “Granuloma”,
“Lymphoid hyperplasia” and “Lymphoma”).
Descriptive analysis used medians with interquartile range (IQR)
values. Statistical comparisons between the 3 NK groups (b50, 50–99,
≥100) were based on the non-parametric Kruskal–Wallis test for con-
tinuous variables and were based on Pearson's chi-square test or
Fisher's exact test when appropriate for comparison of proportions of
patients in multiple groups. Given the large list of clinical and biological
characteristics compared between the 3 NK groups, we report
Benjamini–Hochberg adjusted P values (Pc), which maintains the false
discovery rate at the nominal alpha 0.05 level (Benjamini–Hochberg,
1995). Overall survival (OS) was calculated from inclusion in DEFI
study until the last visit or death from any cause. Follow-up ended in
April 2014. Survival was estimated by the Kaplan–Meier product-limit
method. For OS comparisons, the groups considered were severe, mild
and noNK cell lymphopenia, and then a second analysis was performed
in 4 groups, as a function of NK cell and/or CD4+ T cell deﬁciency, and
the log-rank test was used. Statistical analyses were performed with
STATA Statistical Software version 11.1 (Stata Corp., College Station,
TX, USA).
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(PHRC 2005) and by the French National Centre for Hereditary Immune
Deﬁciencies (CEREDIH), the Laboratoire Français du fractionnement et
des Biotechnologies (LFB) and Baxter BioScience.
3. Results
3.1. Patient Population, Clinical Events and Treatments
Within the DEFI study, 466 patients were diagnosed with CVID, and
NK cell counts at inclusion were available for 457 of these patients.
We found that 99 of these 457 patients (21.7%) had severe NK cell lym-
phopenia (b50 × 106/L), 118 (25.8%) had mild NK cell lymphopenia
(50–99 × 106/L) and 240 (52.5%) had normal NK cell counts
(≥100 × 106/L) (Fig. 1). The demographic and diagnostic characteristics
of these three groups of patients are presented in Table 1. Sex ratio, me-
dian age at onset, at diagnosis and at evaluation, and the proportion of
patients diagnosed before the age of 15 years were similar in these
three groups. A trend towards a higher prevalence of consanguineous
families was noted in the severe NK cell lymphopenia group (8·3% ver-
sus 4·4% and 5%, respectively).
Among these 457 patients, 275 patients (60.2%) presented infections
only, whereas 182 patients (39.8%) presented both infections and other
disease-related complications. The principal clinical events in CVID pa-
tients, according to their NK cell counts, are presented in Table 2. The
prevalence of other disease-related complications (i.e. noninfectious
complications) was higher in the group with severe NK cell lymphope-
nia than in the other two groups (57% vs. 36% and 35%, respectively;
Pc = 0.02) (Fig. 2). The prevalence of tumours, including both solid tu-
mours and lymphoma, was not signiﬁcantly higher in the group with
severe NK cell lymphopenia (19.2% vs. 16.9% and 14.2%, respectively),
whereas granulomatous complications (25.3% vs. 13.6% and 8.8%, re-
spectively), lymphoid hyperplasia (35.4% vs. 24.6% and 19.2%, respec-
tively), enteropathies (41.4% vs. 28% and 24.2%) and autoimmune
cytopenia (25.3% vs. 12.7% and 14.6%) appeared to be more frequent
in the group with severe NK cell lymphopenia than in the other groups,
but after adjustment for multiple testing by Benjamini–Hochberg cor-
rection, only the prevalence of granulomatous complications was
found to be signiﬁcantly higher in the group with severe NK cell lym-
phopenia (Pc b 0.001) (Fig. 2).
The proportions of patients with different types of infectious events
in each group are presented in Fig. 3. Viral infection episodes were
equally frequent in each of the groups (20.2%, 22.9% and 17.1%, respec-
tively). No susceptibility to a particular type of viral infection, such asFig. 1. Flow chart of theHerpes viruses or Human papillomavirus, was noted in the group with
severe NK cell lymphopenia (Supplemental data Tables S1 and S2). Op-
portunistic infections, consistent with the revised classiﬁcation system
of themanifestations of human immunodeﬁciency virus (HIV) infection
(From the Centers for Disease Control and Prevention, 1993), were ob-
served in 10 (10.1%), 4 (3.4%) and 14 (5.8%) patients from the groups
with severe NK cell lymphopenia,mildNK cell lymphopenia and normal
NK cell counts, respectively (Supplemental Table S2). Unusual infec-
tions, deﬁned as atypical infectious events not consistent withmanifes-
tations of HIV infection, were found in 18 (20.9%), 31 (27.4%) and 52
(22%) patients from the groups with severe NK cell lymphopenia, mild
NK cell lymphopenia and normal NK cell counts, respectively (Supple-
mental data Table S1). Severe infectious complications were grouped
together to form an “invasive infections” category, including septicemia,
pneumonia and meningitis. Invasive infections were more frequently
observed among patients with severe and mild NK cell lymphopenia
than among patients with normal NK cell counts (68.7% vs. 60.2% and
48.8%; Pc = 0.05; Fig. 3). Pneumonia (63.6% vs. 59.3% and 44.2%; Pc =
0·02) and septicemia (22.2% vs. 5.9% and 8.3%; Pc b 0.001) were more
frequent in patients with severe NK cell lymphopenia than in patients
from the other two groups. Streptococcus pneumoniaewas documented
in 28 patients from the severe NK cell lymphopenia group, 26 patients
from the mild NK cell lymphopenia group, and 43 patients from the
group with normal NK cell counts (22.4%, 19% and 16.4%, respectively,
of the pneumonia episodes in each group). Haemophilus inﬂuenzae
was documented in 12 patients from the severe NK cell lymphopenia
group, 10 patients from the mild NK cell lymphopenia group, and nine
patients from the group of patients with normal NK cell counts (9.6%,
14.3% and 3.4%, respectively, of the pneumonia episodes in each
group). Other pathogens documented during pneumonia episodes
were less frequent and are detailed in Supplemental Table S3. The path-
ogens identiﬁed in cases of septicemia were gram-negative bacilli in 7
(35% of septicemia episodes in the severe NK cell lymphopenia
group), 3 (42.9% of septicemia episodes in themildNK cell lymphopenia
group) and5 (26.3% of septicemia episodes in the group of patientswith
normal NK cell counts) patients, and gram-positive cocci were identi-
ﬁed in 13 (65% of septicemia episodes), 4 (57.1%) and 14 (73.7%) pa-
tients from the severe NK cell lymphopenia, mild NK cell lymphopenia
and normal NK cell count groups, respectively.
Immunoglobulin (Ig) replacement therapy at inclusion in the DEFI
study was administered to 86.9% of patients with severe NK cell lym-
phopenia, 75.2% of patients with mild NK cell lymphopenia and 65.4%
of patients with normal NK cell counts (Pc b 0.001). Nine patients
(9.1%) in the group with severe NK cell lymphopenia, 5 patients“NK-DEFI” study.
Table 1
Demographic, diagnostic and therapeutic characteristics of three groups of patients with CVID deﬁned on the basis of NK cell counts (b50, 50–99 and ≥100 × 106/L).
Demographic, diagnostic and therapeutic characteristics NK b 50
(n = 99)
NK 50–99
(n = 118)
NK ≥ 100
(n = 240)
Pc
Sex, n (%) male patients 49/99 (49.5) 46/118 (39.0) 100/240 (41.7) ns
Patients with known consanguinity, n (%) 8/93 (8.6) 5/110 (4.5) 12/229 (5.2) ns
Age at onset (years) 19.8 [11.7–34.8] 22.5 [11.5–36.0] 21.5 [10.4–38.1] ns
Age at diagnosis (years) 34.9 [24.0–46.1] 34.3 [21.6–49.1] 36.8 [25.0–52.6] ns
Age at evaluation (years) 44.1 [29·6–55.9] 40.5 [27.7–55.3] 44.8 [33.8–57.8] ns
Patients with diagnosis before the age of 15 years, n (%) 8/99 (8.1) 14/118 (11.9) 24/240 (10.0) ns
Time from onset to diagnosis (years) 9.3 [2.4–17.8] 6.0 [1.2–15.1] 6.5 [1.1–18.5] ns
Ig replacementa, n (%) 86/99 (86.9) 88/117 (75.2) 157/240 (65.4) b10−3
Splenectomy, n (%) 9/99 (9.1) 5/116 (4.3) 24/240 (10.0) ns
Corticosteroid use during disease course, n (%) 15/99 (15.2) 13/113 (11.5) 21/235 (8.9) ns
Immunosuppressive drug use during disease course, n (%) 2/99 (2.0) 3/115 (2.6) 6/237 (2.5) ns
Note. For ages at onset, diagnosis, and evaluation, and time to diagnosis, the median is shown [with 25th and 75th percentiles]. All P values were adjusted by Benjamini–Hochberg pro-
cedure (Pc); ns = not statistically signiﬁcant.
a Ig replacement at evaluation in the DEFI study (corresponding to diagnosis for a part of patients).
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(10%) in the groupwith normal NK cell counts underwent splenectomy.
Corticosteroids had been used in 15 patients (15.2%)with severe NK cell
lymphopenia, 13 patients (11.4%) with mild NK cell lymphopenia and
21 patients (8.9%) with normal NK cell counts. Other immunosuppres-
sive treatments were less frequently prescribed and were found in
only two patients from the severe NK cell lymphopenia group (2%),
three patients from the mild NK cell lymphopenia group (2.5%) and
six 6 patients (2.5%) in the normal NK cell count group (Table 1).
3.2. Immunologic Evaluation
The results of the analyses of the principal lymphocyte subsets at in-
clusion, serum immunoglobulin levels at diagnosis, and comparisons
between patients with severe NK cell deﬁciency and patients with
mild or no NK cell lymphopenia are provided in Table 3.
Total lymphocyte counts were lower in patients with severe NK cell
lymphopenia (median: 967 x106/L) than in patients with mild NK cell
lymphopenia (median: 1331 × 106/L) or normal NK cell countsTable 2
Clinical events in three groups of patients with CVID deﬁned on the basis of NK cell counts (b5
Clinical events NK b 50
(n = 99)
Infections only, % (n) 43.4 (43/99)
Other disease-related complications
Tumours, % (n)
(solid tumours and lymphoma)
19.2 (19/99)
Lymphoid hyperplasia,a % (n) 35.3 (35/99)
Granuloma, % (n) 25.3 (25/99)
Autoimmune disease,b % (n) 13.1 (13/99)
Autoimmune cytopenia, % (n) 25.3 (25/99)
Enteropathy,c % (n) 41.4 (41/99)
Infectious manifestations
Unusual infections, % (n) 20.9 (18/86)
Opportunistic infections, % (n) 10.1 (10/99)
Viral infections, % (n) 18.2 (18/99)
Digestive infections, % (n) 29.3 (29/99)
Invasive infections, % (n)
(pneumonia + septicaemia + meningitis)
68.7 (68/99)
Infectious pneumonia, % (n) 63.6 (63/99)
Sepsis, % (n) 22.2 (22/99)
Meningitis, % (n) 8.1 (8/99)
Note. All P values were adjusted by Benjamini–Hochberg procedure (Pc); ns = not statistically
a Lymphoid hyperplasia: any follicular hyperplasia or polymorph lymphoid inﬁltrate (withou
tonsils, cavum) or within extra-nodal/extra-lymphoid organ;
b Autoimmune disease: autoimmune diseases excluding autoimmune cytopenia (rheumato
Biermer disease, type 1 diabetes, inﬂammatory myositis…);
c Enteropathy: any cause of recurrent acute diarrhea or chronic diarrhea, including celiac-lik
lymphoid hyperplasia or lymphoma in the gut were not included in this category but in the co(median: 1629 × 106/L) (Pc = 0.003). Within the T-cell population, ab-
solute numbers of CD4+ T cells were lower in patients with severe NK
cell deﬁciency (median: 415 × 106/L) than in the other two groups (me-
dian: 568 × 106/L and 691 × 106/L, respectively) (Pc = 0.003). The
counts of naïve CD4+ T cells (deﬁned as CD4+CD45RA+CCR7+ cells)
were also lower in patients with severe NK cell deﬁciency (median:
63 × 106/L) than in the other groups (135 × 106/L and 183 × 106/L, re-
spectively) (Pc = 0.003). Severe CD4+ T-cell deﬁciency (CD4+ T
cells b 200 × 106/L) affected 8·1% of the patientswith severe NK cell de-
ﬁciency, and severe naive CD4+ T-cell deﬁciency (naive CD4+ T
cells b 20 × 106/L) (late-onset combined immunodeﬁciency or
“LOCID” patients according to Malphettes and colleagues (Malphettes
et al., 2009)) was found in 25.3% of the patients with severe NK cell de-
ﬁciency (12.0% and 9.7% respectively in the 2 other groups) (Pc =
0.025).
Total B cell counts were also lower in patients with severe NK cell
lymphopenia than in patients from the other two groups (median:
59 × 106/L vs. 99 × 106/L and 122 × 106/L) (Pc = 0·003). Furthermore,
16.5% of patients with severe NK cell lymphopenia had a CD19+ B cell0, 50–99 and ≥100 × 106/L).
NK 50-99
(n = 118)
NK ≥ 100
(n = 240)
Pc
63.6 (75/118) 65.4 (157/240) 0.02
16.9 (20/118) 14.2 (34/240) ns
24.6 (29/118) 19.2 (46/240) ns
13.6 (16/118) 8.8 (21/240) b10−3
17.8 (21/118) 16.7 (40/240) ns
12.7 (15/118) 14.6 (35/240) ns
28.0 (33/118) 24.2 (58/240) ns
27.4 (31/113) 22 (52/236) ns
3.4 (4/118) 5.8 (14/240) ns
22.9 (27/118) 16.7 (40/240) ns
19.5 (23/118) 18.3 (44/240) ns
60.2 (71/118) 48.8 (117/240) 0.05
59.3 (70/118) 44.2 (106/240) 0.02
5.9 (7/118) 8.3 (20/240) b10−3
5.1 (6/118) 7.5 (18/240) ns
signiﬁcant.
t argument for lymphoma) occurring within lymphoid organ (lymphadenopathy, spleen,
id arthritis, systemic lupus erythematosus, Sjögren syndrome, autoimmune thyroiditis,
e villous atrophy and Crohn's-like inﬂammatory bowel disease. Documented granuloma,
rresponding ones (respectively “Granuloma”, “Lymphoid hyperplasia” and “Lymphoma”).
Fig. 2. Proportion of CVID patients with “other disease-related complications”, i.e. non-infectious complications, according to NK cell count. Percentage of patients with A. other disease-
related complications, B. granuloma, C. tumours, D. lymphoid hyperplasia, E. enteropathy and F. autoimmune cytopenia. In black, patients with severe NK cell deﬁciency; in grey, patients
with mild NK cell lymphopenia; and in white, patients with normal NK cell counts. The statistical tests were two-tailed and the P values were then adjusted for multiple testing, by
Benjamini–Hochberg procedure, for each type of complications (B to F).
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the EuroClass classiﬁcation (Wehr et al., 2008)), versus only 12.3% of pa-
tients with mild NK cell lymphopenia and 7.7% of patients with normal
NK cell counts. Within the B-cell compartment, the median percentage
of IgD−CD27+ switched memory B cells was 1%, 2% and 3% of B cells in
patients with severe, mild and no NK cell deﬁciency, respectively. Ex-
pansion of CD21low B cells has been associated with lymphoprolifera-
tive and autoimmune manifestations during CVID. Number of
CD21low B cells was available in n = 209 patients of our study and a
correlation between CD21low B cells and NK cells numbers was ob-
served (r = 0.13, P= 0.05).
Little is known about the stability of peripheral circulating NK cell
counts in humans. We therefore checked the stability of NK cell counts
over time in 35 patients from the principal center participating in the
DEFI study (Saint-Louis Hospital, Paris). These patients underwent sev-
eral phenotypic investigations, all carried out at the same reference lab-
oratory, during follow-up. Ten of these 35 patients presented severe NK
cell lymphopenia (b50 × 106/L) at inclusion and, for 80% of theseFig. 3. Proportion of CVID patients with different types of infection, as a function of NK cell co
infections, D. sepsis, E. infectious pneumonia. In black, patients with severe NK cell deﬁcien
counts. The statistical tests were all two-tailed and the P values were adjusted for multiple tespatients, NK cell counts remained below 100 × 106/L over time. For
the 15 patients with NK cell counts N100 × 106/L at inclusion, NK cell
counts remained above 100 × 106/L over time in 73% (data not
shown). Thus, NK cell lymphopenia and normalNK cell counts appeared
to remain stable over time in most of these patients. Furthermore no
correlation was observed between age at evaluation or age at diagnosis
and NK cell count in our patients (data not shown).
Median serum immunoglobulin (Ig) G levels at diagnosis were
lower in patients with severe andmild NK cell lymphopenia than in pa-
tients with normal NK cell counts (Pc=0.003). IgA and IgM levels at di-
agnosis were also lower in patients with severe NK cell lymphopenia
than in the other groups (Pc = 0.003 and Pc = 0.005 respectively).
3.3. Survival and Analysis of Subgroups Deﬁned on the Basis of NK and
CD4+ T Cell Counts
Survival ﬁve years after inclusion in the DEFI studywas 86.7% for the
severe NK cell lymphopenia group, 92.6% for the mild NK cellunt. Percentage of patients with A. viral infections, B. opportunistic infections, C. invasive
cy; in grey, with mild NK cell lymphopenia; and in white, patients with normal NK cell
ting, by Benjamini-Hochberg procedure.
Table 3
Lymphocyte subsets at inclusion in the DEFI study and immunoglobulin levels at diagnosis, for patients with CVID and severe, mild or no NK cell lymphopenia.
Biological characteristics NK b 50
(n = 99)
NK 50–99
(n = 118)
NK ≥ 100
(n = 240)
Reference values Pc
Total lymphocytes (×106/L) 967 [693–1187] 1331 [1030–1739] 1629 [1293–2236] 1922 [1524–2503] 0.003
CD3 (×106/L) 801 [548–1029] 1079 [818–1436] 1204 [939–1657] 1419 [1122–1774] 0.003
CD4 (×106/L) 415 [277–571] 568 [380–779] 691 [495–927] 912 [682–1153] 0.003
CD4 b 200 × 106/L
n (% of patients)
8/99 (8.1) 8/118 (6.8) 9/240 (3.8) – ns
Naive CD4 (×106/L) 63 [20–132] 135 [41–246] 183 [64–349] 363 [295–550] 0.003
Naive CD4 b 20 × 106/L
n (% of patients)
25/99 (25.3) 14/117 (12.0) 23/237 (9.7) – 0.025
CD8 (×106/L) 310 [198–474] 431 [339–598] 479 [332–672] 474 [356–616] 0.003
CD19 (×106/L) 59 [19–116] 99 [46–172] 122 [69–209] 202 [126–301] 0.003
“no-B” (CD19 b 1%)
n (% of patients)
16/97 (16.5) 14/114 (12.3) 18/233 (7.7) – ns
CD19+IgD−CD27+ (%) 1 [0.5–3.0] 2 [0.7–7.0] 3 [1·0–9.0] 14.5 [10.0–19.5] 0.003
“SmB-” n (% of patients) 55/97 (56.7) 52/114 (45.6) 84/233 (36.1) – ns
IgG (at diagnosis) (g/L) 1.98 [0.80–2.90] 2 [0.72–3.54] 3.42 [1.70–4.45] NR: 6.72–12.48 0.003
IgA (at diagnosis) (g/L) 0.09 [0.06–0·26] 0.18 [0.07–0.34] 0·26 [0.09–0.67] NR: 1.00–3.18 0.003
IgM (at diagnosis) (g/L) 0.19 [0.10–0·30] 0.22 [0.10–0.42] 0.3 [0.17–0.56] NR: 0.55–1.55 0.005
Note. For absolute values and percentages of lymphocyte subsets and immunoglobulins, themedian is shown [with 25th and 75th percentiles]. For lymphocyte subsets analysis, reference
values correspond to the control population of 52 healthy blood donors. For immunoglobulins, reference values correspond to normal range (NR) of the laboratory. All P values were ad-
justed by Benjamini–Hochberg procedure (Pc); ns = not statistically signiﬁcant.
Fig. 4. A. Overall survival in three groups of patients with CVID deﬁned on the basis of NK
cell counts (b50, 50–99 and ≥100 × 106/L) (P=0.16). B. Overall survival in four groups of
patients with CVID deﬁned on the basis of NK cell (b50 and ≥50 × 106/L) and CD4+ T cell
(b200 and ≥200 × 106/L) counts (P b 10−3). All statistical tests were two-tailed.
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cell counts at inclusion (P = 0.16). Kaplan–Meier curves were plotted
(Fig. 4A).
Low CD4+ T cell count is known to be associatedwith higher rates of
mortality and clinical events in patients with CVID (Malphettes et al.,
2009), and patients with severe NK-cell deﬁciency also have lower
CD4+ T cell counts in our study. The cut-off of 200 × 106/L CD4+ T
cellswas based on the results of a previouswork showing that a peculiar
phenotype of “LOCID” (Late Onset Combined ImmunoDeﬁciency) was
observed in CVID patients with CD4+ T cells below this value and on
the basis of 2014 ESID deﬁnition of CVID patients with profound T-cell
defect (Ameratunga et al., 2014).We studied survival and clinical events
in four subgroups of patients deﬁned on the basis of NK and CD4+ T cell
counts (Supplemental Fig. S2): a “T−NK−” group (8patientswith both
CD4+ T cell counts b 200 × 106/L and NK cell counts b 50 × 106/L), a
“T−NK+” group (18 patients with CD4+ T cells b 200 × 106/L and
NK cells ≥ 50 × 106/L), a “T+NK−” group (91 patients with CD4+ T
cells ≥ 200 × 106/L and NK cells b 5 × 106/L) and a “T + NK+” group
(351 patients with both CD4+ T cells ≥ 200 × 106/L and NK
cells ≥ 50 × 106/L). Survival in these four subgroups of CVID patients is
presented in Fig. 4B. Mortality was particularly high in the subgroup
of patients with both NK cell and CD4+ T cell deﬁciencies (the
“T−NK−” group), as survival at 5 years was 93.2%, 89.5%, 71.6% and
58.3% for the “T+NK+”, “T+NK−“, “T−NK+” and “T−NK−“sub-
groups, respectively (P b 0.0001). The prevalence of septicemia (Fig.
5) and pneumonia was higher in the “T−NK−” (50% of patients for
septicemia and 87.5% of patients for pneumonia) and “T + NK−”
(19.8% of patients for septicemia and 61.5% of patients for pneumonia)
subgroups, and lower in the “T−NK+” (5.6% and 61.1%, respectively)
and “T+NK+” (7.4% and 48.7% respectively) subgroups. Other
disease-related complications (non-infectious clinical events) were ob-
served in respectively 4/8 patients in the “T−NK−“ group (50.0%), 11/
18 patients in the “T−NK+” group (61.1%), 52/91 patients in the
“T+NK−“ group (57.1%) and 120/351 patients in the “T+NK+ ”
group (34.2%).
4. Discussion
Large cohorts for studying the correlation between NK cell deﬁcien-
cy and clinical events in humans are extremely rare. The study by Imai
and colleagues (Imai et al., 2000) reporting correlation between low
NK cell cytotoxicity and the incidence of cancer in a cohort of 3625 pa-
tients is the only such study published to date. Our study is original inaddressing the role of NK cells in a large cohort of immunodeﬁcient pa-
tients through exploration of the phenotype of patients with quantita-
tive NK cell deﬁciency.
Fig. 5. Proportion of patients with sepsis in four subgroups of CVID patients deﬁned on the
basis of NK cell (b50 and ≥50 × 106/L) and CD4+ T cells (b200 and ≥200 × 106/L) counts.
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justiﬁed by the conclusion of a probable redundant role of these cells in
humans reported by some studies in patients with “selective” NK cell
deﬁciency. Studies of NK cell deﬁciency in patients with concomitant
defect of one or several components of adaptive immunity, as in CVID
patients, could thus reveal redundant in vivo functions of NK cells in
humans.
Different classiﬁcations and subgroups of CVID patients have been
proposed, deﬁned on the basis of the quantitative abnormalities of B
cells and T cells (Malphettes et al., 2009;Wehr et al., 2008), but data re-
garding theNK cell compartment of these patients and thephenotype of
CVID patients with NK cell deﬁciency are rare. Few studies have already
evaluated number of NK cells in CVIDpatients and observed a decreased
number of NK cells in these patients (Aspalter et al., 2000; Berrón-Ruiz
et al., 2014; Kutukculer et al., 2015). Nevertheless, our study is unique in
reporting clinicalmanifestations and phenotype of patientswithNK cell
deﬁciency, especially in a cohort as large as more than 450 CVID pa-
tients. In 2000 Aspalter and colleagues reported a decrease in absolute
and relative numbers of NK cells (deﬁned as CD3−CD16+ cells) in 55
CVID patients compared to healthy controls, but without study of clini-
calmanifestations associatedwith thisNK cell deﬁciency (Aspalter et al.,
2000). In 2015 Kutukculer and colleagues explored innate immunity in
a small cohort of 20 pediatric CVID patients, with decreased percentage
and increased cytotoxicity of NK cells in patients with severe disease
(depending on the presence of splenomegaly, granuloma and/or bron-
chiectasis), but without detail about each of these clinical manifesta-
tions and other complications of the disease (Kutukculer et al., 2015).
In the study of Aspalter et al., a decrease of invariant NK T cells has
also been found in CVID patients, with again difﬁculties to conclude
without available clinical data in this study (Aspalter et al., 2000). Final-
ly, type 1 innate lymphoid cells (ILCs) can share phenotypical markers,
such as CD56, with bonaﬁdeNK cells (Hazenberg and Spits, 2014) and a
type 1 ILCs defect could potentially contribute to the observed pheno-
type of patients with NK cell deﬁciency.
Interestingly, although there is a large body of evidence concerning
the role of NK cells in defense against viral pathogens (Lugli et al.,
2014; Della Chiesa et al., 2014; Lee et al., 2007), the proportion of pa-
tients with viral infections did not differ between groups deﬁned on
the basis of their circulating NK cell counts in this large population of
CVID patients. We also found no qualitative evidence for susceptibility
to a particular type of virus in patientswith severe NK cell lymphopenia.
For example, Human papilloma virus (HPV) infectionswere equally fre-
quent in all groups of patients, despite reports implicating NK cells in
the control of infections with this pathogen (Kamili et al., 2014; Bere
et al., 2014). Similarly, CMV infections did not appear to be more fre-
quent in patients with severe NK cell deﬁciency than in patients with
mild or no NK cell deﬁciency in our study. Difﬁcult formal diagnosis ofviral pathogens in clinical practice in these hypogammaglobulinemic
patients, underestimation of benign viral episodes, or compensation
by T cell compartment in this adult population could be as many expla-
nations for this apparent discrepancy between earlier reports and our
present study. In any event, these data highlight that the demonstration
of a non-redundant role of NK cells in the control of viral infections has
been obtained in the mouse, but not formally in humans.
The role of NK cells in anti-tumour responses has been extensively
studied, for various types of tumour, in animal models and humans
(Vivier et al., 2012; Shafer et al., 2013; Velardi et al., 2012). Imai and col-
leagues reported that low peripheral NK cell cytotoxicitywas associated
with a higher incidence of cancer (Imai et al., 2000). Surprisingly, in our
study comparing CVID patients with different counts of peripheral NK
cells, no differences between groups were observed for the incidence
of neoplasms, including solid tumours and lymphomas. The median
time from the onset of symptoms and evaluation in this study was 18
to 24.3 years in the groups studied, and the duration of follow-up
would also be unlikely to account for this lack of association. The rela-
tively young age at evaluation (median: from 40.5 to 44.8 years, de-
pending on the group considered) in the DEFI study may account for
the missing cancers, as many tumours occur after the age of 50 years
(most of the events in the study by Imai and colleagues) (Imai et al.,
2000).
The main ﬁnding in this study was the high frequency of invasive
bacterial infections in CVID patients with severe NK cell lymphopenia
(68.7%). This frequency was higher than that in patients with mild
(60.2%) or no NK cell lymphopenia (48.8%). This higher incidence of se-
vere bacterial infections was accounted for by a higher incidence of
pneumonia and sepsis/bacteremia in particular, with bacteremia being
found in 22.2% of patients with severe NK cell lymphopenia (versus
only 5.9% and 8.3% of the patients in the other two groups). This higher
incidence of severe bacterial infection did not seem to be related to the
proportion of splenectomised patients, similar in the 3 studied groups,
or to be related to an associated CD4+ T cell deﬁciency, because it
persisted in the NK−T+ group, particularly for sepsis/bacteremia. Sev-
eral studies have reported protective or deleterious roles of NK cells in
various models of bacterial infectious diseases. A protective role for
NK cells was demonstrated for infections with Listeria monocytogenes,
Mycobacterium avium, Mycobacterium tuberculosis and various strains
of Salmonella (Katz et al., 1990; Harshan and Gangadharam, 1991;
Bermudez et al., 1990; Wherry et al., 1991; Vankayalapati et al., 2005).
Similarly, NK cells have been shown to play a critical protective role in
septic arthritis and models of pulmonary infection with Staphylococcus
aureus (Nilsson et al., 1999; Small et al., 2008). The mildly protective
role of NK cells in these bacterial infections is thought to involve IFN-γ
secretion, promoting macrophage phagocytic functions and/or the
lysis of infected macrophages through the recognition of as yet uniden-
tiﬁed activation ligands (Souza-Fonseca-Guimaraes et al., 2012). By
contrast, deleterious effects of NK cell activation were reported after in-
fection with gram-negative bacteria such as with Escherichia coli
(Badgwell et al., 2002) or gram-positive bacteria such as with S.
pneumoniae (Kerr et al., 2005). In these conditions, NK cells have been
shown to contribute to septic shock (Barkhausen et al., 2008; Carson
et al., 1999; Emoto et al., 2002; Heremans et al., 1994), but their deple-
tion in S. pneumoniae-infected mice has also been reported to impair
bacterial clearance (Elhaik-Goldman et al., 2011). The dual role of NK
cells, which may be initially beneﬁcial, helping to control bacterial
load, but may then become deleterious in the acute phase of sepsis, me-
diating tissue damage, requires further investigation.
The prevalence of non-infectious disease-related complications,
such as granuloma in particular, was also found to be higher in patients
with severe NK cell lymphopenia than in patients with mild or no NK
cell lymphopenia. In a description of 59 patients with granulomatous
disease and CVID from theDEFI study, patients with granulomatous dis-
ease had lower NK cell counts (median: 60 × 106/L) than patients with-
out granulomatous disease (median: 109 × 106/L) (Boursiquot et al.,
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granulomatous disease and CVID (Ardeniz and Cunningham-Rundles,
2009; Bouvry et al., 2013; Mullighan et al., 1997). The etiology and
mechanisms involved in granuloma in patients with CVID have yet to
be elucidated. Granulomamay be a consequence of a persistent but un-
detected infection with a virus or another microorganism, leading to
weaker cell-mediated, and possibly NK cell immunity. Consistent with
this hypothesis, Bodemer and colleagues recently described the long-
term persistence of live rubella virus vaccine as an antigenic trigger of
cutaneous granulomas in patients with primary immunodeﬁciency
(Bodemer et al., 2014). Advanced DNA sequencing technologies might
be able to detect the presence in granuloma lesions of microbes not de-
tected in conventional in vitro growth assays.
Although the ﬁrst of its kind, our study has some limitations. Firstly,
our results are based on clinical observations and measurements, with
mostly retrospective data collection, and a statistical correlation cannot
be interpreted as indicative of a causal relationship. Given the explor-
atory nature of this study, we carried out multiple hypothesis testing
using the Benjamini–Hochberg method to control for false discovery
rate. However these results should be interpreted with caution, and
we cannot conclude that all signiﬁcances are really cases, but most
rejected hypotheses (e.g., around 95%) correspond to cases where the
alternative hypothesis is true. The stability of NK cell counts in these pa-
tients over time is also a non-resolved issue.
Another key point relates to the lower counts of CD4+ T cells, naïve
CD4+ T cells and B cells in the group of patientswith severe NK cell lym-
phopenia. Indeed, severe CD4+ T cell deﬁciency and naïve CD4+ T cell
deﬁciency have been associated with the “LOCID” phenotype, with a
high frequency of non-infectious disease-related complications and op-
portunistic infections (Malphettes et al., 2009). Similarly, the “no-B”
phenotype (B cells b 1%) and the presence of dysregulated B-cell sub-
populations (low proportions of switched memory B cells, high transi-
tional and CD21low B cell counts) are associated with clinical
complications, such as splenomegaly, lymphadenopathy and granulo-
ma (Wehr et al., 2008). In this line, higher rates of invasive infections
and non-infectious complications observed in patients with NK cell de-
ﬁciency could be explained by global, T and B cell lymphopenia ob-
served in these patients. Nevertheless, patients with the “no-B″
phenotype, severe CD4+ T cell deﬁciencies (b200 × 106/L) and very
low naïve CD4+ T cell counts (b20 × 106/L) accounted for “only”
16.5%, 8.1% and 25.3%, respectively, of the patients with severe NK cell
deﬁciency, suggesting that these factors alone cannot account for the
observed phenotype of patients with severe NK cell lymphopenia. The
persistence of a higher frequency of pneumonia and bacteremia in the
T+NK− subgroup also suggests that NK cells could contribute to this
phenotype. Although the coexistence of T cell and B cell deﬁciencies as-
sociated in these patients introduce some difﬁculties in interpreting the
clinical manifestations observed, we are convinced that it is in these
“non-redundant” conditions of associated adaptive immune system de-
ﬁciency that NK cell deﬁciency could be clinically relevant. Unfortunate-
ly, to show strictly and statistically this point, comparison should be
performed between T−(B−)NK− and T−(B−)NK+ groups, but
these groups are the smallest groups (most uncommonpatients)within
our large cohort of CVID patients, with only respectively 8 and 18 pa-
tients. These numbers do not enable us to make stringent statistical
analysis on the independent role of NK cells. Finally, the coexistence of
T, B and NK cell deﬁciencies in some patients with CVID raises questions
about the possibility of an as yet unidentiﬁed genetic defects leading to
global lymphopoietic deﬁciencies in at least some of these patients
(Ochs, 2014).
Mortality was not signiﬁcantly higher in patients with severe NK cell
deﬁciency than in patients with mild or no NK cell deﬁciency in our
study. Nevertheless, mortality was particularly high (41.7% at 5 years)
in the subgroup of patients with both severe NK cell lymphopenia and
a severe CD4+ T cell deﬁciency. This suggests that NK cells could play
a non-redundant role when the adaptive immune system, and theCD4 compartment in particular, is not optimal. Another recent study
in 40 patients with idiopathic CD4 lymphopenia reported similar con-
clusions, with a correlation between low peripheral NK cell counts,
and a high frequency of infections and low survival in these patients
(Régent et al., 2014). In the same line, a recent study in ﬁve unrelated
children with inherited DOCK2 deﬁciency, leading to T-cell, B-cell, and
NK-cell defective responses, found early-onset invasive bacterial infec-
tions in these patients (Dobbs et al., 2015).
In conclusion, this large cohort study of CVID patients, despite some
limitations, provides new insight into the functions of NK cells in vivo.
Patientswith CVID andNK cell deﬁciency seem to have a particular phe-
notype, with high frequencies of severe bacterial infections (pneumonia
and bacteremia), and non-infectious disease-related complications,
such as granuloma in particular. These data suggest that we should re-
consider the role of human NK cells in controlling non-viral infections,
such as extracellular bacterial infections in particular. The high frequen-
cy of these pathological events in this group of patients, and the high
mortality of the T−NK− subgroup suggest that NK cells may have
non-redundant immune functions in humans when the adaptive im-
mune response is not optimal, and that reciprocally NK cells exert re-
dundant functions in natura in normal individuals, at least in adults.
This observation and the absence of a speciﬁc phenotype in SCID pa-
tients displaying a failure to reconstitute the NK compartment after
HSCT suggest that there may be cooperation between T cells and NK
cells, with NK cells helping to protect against pathogenic bacteria in
the absence of T cells but becoming redundant if T cells are present. Sev-
eral advantages are associated with redundant mechanisms. First, they
can provide robust fail-safe mechanisms that ensure adequate protec-
tion (Nish and Medzhitov, 2011). Second, they can also limit the risk
of immunopathologies, by ensuring the limited activation of each lym-
phocyte subset on challenge (Nish and Medzhitov, 2011). Our results
thus pave the way for dissecting in more detail the interplay between
NK cells, T cells and B cells in the control of bacterial infections in natura.
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